Turn Therapeutics Inc. (TTRX)

Turn Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-3.8	-1.77	-2.29	-4.29
Depreciation & Amortization	0.05	0.05	0.04	0.05
Stock-Based Compensation	0.45	0.35	0.64	1.88
Other Operating Activities	0.01	0.01	0	0.05
Change in Accounts Payable	1.65	0.2	0.21	-0.3
Change in Unearned Revenue	-	-	0.02	1.42
Change in Other Net Operating Assets	-0.18	-0.2	0	-0.01
Operating Cash Flow	-1.82	-1.36	-1.38	-1.21
Sale (Purchase) of Intangibles	-0.13	-0.1	-0.04	-0.02
Investing Cash Flow	-0.13	-0.1	-0.04	-0.02
Issuance of Common Stock	4.26	1.15	0.5	0.35
Financing Cash Flow	4.26	1.15	0.5	0.35
Net Cash Flow	2.32	-0.31	-0.92	-0.87
Levered Free Cash Flow	-	-0.82	-2.01	-
Unlevered Free Cash Flow	-	-0.82	-2.01	-
Change in Working Capital	1.47	-0	0.23	1.1

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q